Literature DB >> 6979306

Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

H C Neu, P Labthavikul.   

Abstract

The in vitro activity of N-formimidoyl thienamycin was determined against 800 gram-positive and gram-negative aerobic and anaerobic bacteria and compared with the activity of cefoxitin, cefazolin, cefamandole, cefotaxime, moxalactam, ampicillin, cefoperazone, and gentamicin. N-Formimidoyl thienamycin inhibited the majority of organisms at concentrations below 1 microgram/ml. It inhibited methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus faecalis. It inhibited beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae. Unlike other new beta-lactams, it inhibited Listeria. Escherichia coli, Klebsiella pneumoniae, enterobacters, Serratia, indole-positive Proteus, Acinetobacter, Pseudomonas aeruginosa, and Bacteroides resistant to other agents were inhibited. There was minimal effect of inoculum size and aerobic versus anaerobic conditions, and serum had no effect on activity. Most minimal bactericidal concentrations were two- or fourfold greater than the minimal inhibitory concentration. N-Formimidoyl thienamycin showed partial synergy with aminoglycosides against S. aureus, S. faecalis, and many Pseudomonas and Enterobacteriaceae. It was not hydrolyzed by plasmid-mediated and chromosomal beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979306      PMCID: PMC181851          DOI: 10.1128/AAC.21.1.180

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

Authors:  S S Weaver; G P Bodey; B M LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

2.  In vitro activity of thienamycin.

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

5.  Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains.

Authors:  M Toda; K Sato; H Nakazawa; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

8.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  8 in total
  69 in total

1.  In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.

Authors:  K Ubukata; M Hikida; M Yoshida; K Nishiki; Y Furukawa; K Tashiro; M Konno; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 2.  The penicillins today.

Authors:  R Finch
Journal:  BMJ       Date:  1990-05-19

3.  A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.

Authors:  G B Calandra; M Hesney; C Grad
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 4.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

5.  In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.

Authors:  Y Sumita; M Inoue; S Mitsuhashi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

6.  Intrathecal penetration of N-formimidoyl thienamycin in normal rabbits: potentiation by coadministration of renal dipeptidase enzyme inhibitor.

Authors:  A W Chow; K R Finlay; H G Stiver; C L Carlson
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

7.  Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci.

Authors:  R M Blumenthal; R Raeder; C D Takemoto; E H Freimer
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

8.  Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.

Authors:  M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

9.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Subinhibitory concentrations of imipenem induce increased resistance to methicillin and imipenem in vitro in methicillin-resistant Staphylococcus aureus.

Authors:  B A Forbes; K D McClatchey; D R Schaberg
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.